ASCO 2022 | Potential of immunotherapy for pancreatic cancer

Vinod P. Balachandran • 16 Jun 2022

Gastrointestinal Cancer Pancreatic Cancer

Immuno-Oncology

Vinod Balachandran, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the potential of immunotherapy in pancreatic cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Phase I trial of mRNA neoantigen vaccines for pancreatic cancer

Vinod P. Balachandran • 16 Jun 2022

Next steps for the development of individualised mRNA neoantigen vaccines

Vinod P. Balachandran • 16 Jun 2022

Related Videos

Highlights in kidney and bladder cancer at ASCO 2023

Benjamin Garmezy • 5 Jul 2023

Efficacy of second-line chemotherapy in advanced CCA with FGFR2 fusions

Milind Javle • 1 Jul 2020

COVID-19 & the management of cancer patients

Alberto F. Sobrero • 3 Jun 2020

HER-2 conversion: a phenomenon in trastuzumab resistance

Russell Petty • 5 Nov 2019